Drug intelligence / Profile preview

PD-DP-006

Development stage: Preclinical
Lead developer: Chengdu Peide Biopharmaceutical
Modality: Small Molecules
Administration: Subcutaneous

Overview

PD-DP-006 is a small molecule therapeutic candidate being developed by Chengdu Peide Biopharmaceutical for the treatment of thrombosis and cardiovascular diseases. As of 2024, the program is in the IND-enabling phase, with an Investigational New Drug (IND) application projected for 2026. The specific molecular target has not been publicly disclosed by the sponsor, but the drug is part of a pipeline focused on innovative treatments for cardiovascular conditions.

Targets

Factor XIa

Beyond the preview

Go deeper on PD-DP-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-DP-006.

Explore the full profile